HK1032349A1 - Melanoma therapy. - Google Patents

Melanoma therapy.

Info

Publication number
HK1032349A1
HK1032349A1 HK01102202A HK01102202A HK1032349A1 HK 1032349 A1 HK1032349 A1 HK 1032349A1 HK 01102202 A HK01102202 A HK 01102202A HK 01102202 A HK01102202 A HK 01102202A HK 1032349 A1 HK1032349 A1 HK 1032349A1
Authority
HK
Hong Kong
Prior art keywords
melanoma therapy
melanoma
therapy
Prior art date
Application number
HK01102202A
Other languages
English (en)
Inventor
Mary Ellen Rybak
Esther Helen Rose
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1032349A1 publication Critical patent/HK1032349A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK01102202A 1999-04-08 2001-03-26 Melanoma therapy. HK1032349A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28836699A 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
HK1032349A1 true HK1032349A1 (en) 2001-07-20

Family

ID=23106795

Family Applications (2)

Application Number Title Priority Date Filing Date
HK01102202A HK1032349A1 (en) 1999-04-08 2001-03-26 Melanoma therapy.
HK05109748.1A HK1075416A1 (en) 1999-04-08 2005-11-02 Melanoma therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK05109748.1A HK1075416A1 (en) 1999-04-08 2005-11-02 Melanoma therapy

Country Status (22)

Country Link
EP (3) EP2025344B1 (hu)
JP (1) JP2000319195A (hu)
CN (1) CN1390132A (hu)
AR (1) AR023398A1 (hu)
AT (3) ATE296639T1 (hu)
AU (1) AU771569B2 (hu)
BR (1) BR0009646A (hu)
CA (1) CA2303992A1 (hu)
CO (1) CO5170404A1 (hu)
CY (1) CY1108922T1 (hu)
DE (3) DE60041290D1 (hu)
DK (2) DK1535622T3 (hu)
ES (2) ES2319776T3 (hu)
HK (2) HK1032349A1 (hu)
HU (1) HU230057B1 (hu)
MY (1) MY126763A (hu)
NO (1) NO328111B1 (hu)
PE (1) PE20010027A1 (hu)
PT (2) PT1043026E (hu)
TW (1) TWI292320B (hu)
WO (1) WO2000061175A2 (hu)
ZA (1) ZA200108173B (hu)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103476943A (zh) 2011-03-10 2013-12-25 普罗维克图斯药品公司 用于增强治疗癌症的局部和全身性免疫调节疗法的组合

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ276943A (en) 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates

Also Published As

Publication number Publication date
NO20014852L (no) 2001-12-06
NO328111B1 (no) 2009-12-07
HUP0200775A2 (en) 2002-08-28
AU4204600A (en) 2000-11-14
WO2000061175A2 (en) 2000-10-19
EP2025344B1 (en) 2011-01-26
ATE496631T1 (de) 2011-02-15
PT1535622E (pt) 2009-03-19
CA2303992A1 (en) 2000-10-08
DE60041290D1 (de) 2009-02-12
HK1075416A1 (en) 2005-12-16
EP1535622B1 (en) 2008-12-31
ZA200108173B (en) 2003-01-06
ES2239954T3 (es) 2005-10-16
BR0009646A (pt) 2002-02-05
AU771569B2 (en) 2004-03-25
DE60020444D1 (de) 2005-07-07
JP2000319195A (ja) 2000-11-21
PE20010027A1 (es) 2001-02-05
AR023398A1 (es) 2002-09-04
DK1535622T3 (da) 2009-04-20
HU230057B1 (hu) 2015-06-29
WO2000061175A3 (en) 2001-02-01
CN1390132A (zh) 2003-01-08
EP1043026B1 (en) 2005-06-01
CY1108922T1 (el) 2014-07-02
EP1043026A2 (en) 2000-10-11
EP2025344A1 (en) 2009-02-18
DE60045591D1 (de) 2011-03-10
DE60020444T2 (de) 2006-05-04
DK1043026T3 (da) 2005-07-04
TWI292320B (en) 2008-01-11
PT1043026E (pt) 2005-09-30
NO20014852D0 (no) 2001-10-05
EP1043026A3 (en) 2000-12-20
ATE419001T1 (de) 2009-01-15
ATE296639T1 (de) 2005-06-15
HUP0200775A3 (en) 2002-09-30
MY126763A (en) 2006-10-31
ES2319776T3 (es) 2009-05-12
EP1535622A1 (en) 2005-06-01
CO5170404A1 (es) 2002-06-27

Similar Documents

Publication Publication Date Title
MXPA01013362A (es) Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso.
ZA200200477B (en) 2-pyrazolin-5-ones.
EG24361A (en) 4-pyrimiding1-n-acy1.l.phenlalanines
ZA200202537B (en) Pour-on-formulations.
HK1051608A1 (en) Single-photon-emission apparatus.
ZA200201829B (en) New phenylpiperazines.
HK1053470A1 (en) 4-Pyridinyln-acyl-l-phenylalanines.
HK1029502A1 (en) Slider-pull-assembling unit.
GB9930570D0 (en) Therapy
GB9907243D0 (en) Therapy
ZA200105690B (en) Novel treatment.
MXPA02000261A (es) Aminoindanos novedosos.
ZA200110046B (en) Therapeutic agents.
GB0029720D0 (en) I.S machine7544232001
HK1032349A1 (en) Melanoma therapy.
ZA200204581B (en) Nitro-sulfobenzamides.
HK1031254A1 (en) Tachogragh.
GB9915251D0 (en) The overguard
GB9905060D0 (en) The saboteur
GB9909067D0 (en) Combination therapy
ZA200007026B (en) Acart.
ZA200001527B (en) De-sleeving.
ZA200007821B (en) Hidroponiese Plantproduksiestelsel.
ZA200203458B (en) Diaryl-enynes.
GB9921063D0 (en) Therapy

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170406